Disease Interactions

Oxcarbazepine Disease Interactions

There are 2 disease interactions with oxcarbazepine:

Oxcarbazepine (Includes Oxcarbazepine) ⇔ Renal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction

The pharmacologically active 10-monohydroxy metabolite (MHD) of oxcarbazepine, as well as other metabolites, are primarily excreted by the kidney. The plasma clearance of MHD may be decreased and the half-life prolonged in patients with impaired renal function. In patients with creatinine clearance < 30 mL/min, the elimination half-life was 19 hours, compared to 9 hours for patients with normal renal function. Therapy with oxcarbazepine should be administered cautiously in patients with significant renal dysfunction. The manufacturer recommends initiating therapy at one-half the usual dosage in patients with moderate to severe renal impairment. Such patients will also require a longer time to reach steady-state at any given dosage.


Oxcarbazepine (Includes Oxcarbazepine) ⇔ Hyponatremia

Moderate Potential Hazard, High plausibility

Applies to: Hyponatremia, Renal Dysfunction, SIADH, Fluid Retention, Adrenal Insufficiency, Hypothyroidism, Polydipsia, Cirrhosis, Congestive Heart Failure

Clinically significant hyponatremia (Na < 125 mmol/L) can develop during the use of oxcarbazepine. In controlled studies, 2.5% of patients receiving oxcarbazepine developed hyponatremia at some point during treatment, generally within the first 3 months but as late as a year or more after initiating therapy. In most cases, the hyponatremia was asymptomatic and serum sodium levels normalized within a few days following withdrawal of the medication without additional treatment. Therapy with oxcarbazepine should be administered cautiously in patients with conditions predisposing to hyponatremia, such as SIADH, use of diuretics or drugs associated with inappropriate antidiuretic hormone secretion, adrenal insufficiency, hypothyroidism, primary polydipsia, and edema (e.g., due to liver cirrhosis, congestive heart failure, or nephrotic syndrome). Serum sodium levels should be monitored during maintenance therapy, and patients should be monitored for signs and symptoms possibly indicating hyponatremia such as nausea, malaise, headache, lethargy, confusion, obtundation, and increase in seizure frequency or severity. If hyponatremia occurs, conservative measures such as fluid restriction, a reduction in dosage, or discontinuation of therapy will usually suffice.


You should also know about...

oxcarbazepine drug Interactions

There are 667 drug interactions with oxcarbazepine

oxcarbazepine food/lifestyle Interactions

There is 1 food/lifestyle interaction with oxcarbazepine

See also...



Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2009 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.


MedNotes
Advertisement

(web1)